The FDA has approved a drug called ubrogepant (Ubrelvy) for the treatment of acute migraine, with or without aura, in adults. The safety and efficacy of the drug were demonstrated in two clinical trials. Developed by Allergan, ubrogepant is expected to be available in the first quarter of 2020.
Related Articles
The post FDA Approves Ubrogepant for the Treatment of Acute Migraine appeared first on Latest Health & Medical News – Myhealthyclick.com.
